Cellectis (NASDAQ:CLLS) Announces Earnings Results

Cellectis (NASDAQ:CLLS) announced its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04, Zacks reports. The business had revenue of $6.90 million during the quarter, compared to analysts’ expectations of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Cellectis Stock Performance

CLLS opened at $1.53 on Friday. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.37 and a quick ratio of 1.37. The firm has a fifty day moving average price of $2.87 and a 200 day moving average price of $3.27. Cellectis has a 1 year low of $1.25 and a 1 year high of $5.48. The stock has a market cap of $153.52 million, a P/E ratio of -2.35 and a beta of 2.92.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Wells Fargo & Company reduced their target price on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday. Weiss Ratings lowered shares of Cellectis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Barclays downgraded Cellectis from an “overweight” rating to an “underweight” rating and cut their price target for the stock from $9.00 to $1.30 in a research report on Wednesday. Robert W. Baird reduced their price objective on Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Citizens Jmp reissued a “market perform” rating on shares of Cellectis in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $5.46.

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.